Brendan M. O'Leary
Director/Board Member at Silk Therapeutics, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Gregory Altman | M | - |
Evolved by Nature, Inc.
 Evolved by Nature, Inc. TextilesProcess Industries Evolved by Nature, Inc. manufactures activated silk. The firm’s product is pure silk in liquid form, a regenerative technology made from discarded silkworm cocoons. The company was founded by Gregory Altman and Rebecca Lacouture in 2013 and is headquartered in Medford, MA.
Silk Therapeutics, Inc.
 Silk Therapeutics, Inc. Specialty StoresRetail Trade Silk Therapeutics, Inc. provides silk protein solutions for human health. It sells its products through its online store. The firm’s PureProC, a film formulation that protects, stabilizes and delivers the use of vitamin C for duration with anti-aging and skin health benefits. The company was founded Gregory H. Altman and Rebecca Horan in June 2013 and is headquartered in Medford, MA. | 11 years |
| Rebecca Lacouture | M | - |
Evolved by Nature, Inc.
Evolved by Nature, Inc. TextilesProcess Industries Evolved by Nature, Inc. manufactures activated silk. The firm’s product is pure silk in liquid form, a regenerative technology made from discarded silkworm cocoons. The company was founded by Gregory Altman and Rebecca Lacouture in 2013 and is headquartered in Medford, MA.
Silk Therapeutics, Inc.
Silk Therapeutics, Inc. Specialty StoresRetail Trade Silk Therapeutics, Inc. provides silk protein solutions for human health. It sells its products through its online store. The firm’s PureProC, a film formulation that protects, stabilizes and delivers the use of vitamin C for duration with anti-aging and skin health benefits. The company was founded Gregory H. Altman and Rebecca Horan in June 2013 and is headquartered in Medford, MA. | 11 years |
| Cynthia Lavoie | M | - |
AllosteRx Capital Management (Canada), Inc.
| 6 years |
| Daniel A. Kraft | M | 59 |
Evolved by Nature, Inc.
Evolved by Nature, Inc. TextilesProcess Industries Evolved by Nature, Inc. manufactures activated silk. The firm’s product is pure silk in liquid form, a regenerative technology made from discarded silkworm cocoons. The company was founded by Gregory Altman and Rebecca Lacouture in 2013 and is headquartered in Medford, MA.
Silk Therapeutics, Inc.
Silk Therapeutics, Inc. Specialty StoresRetail Trade Silk Therapeutics, Inc. provides silk protein solutions for human health. It sells its products through its online store. The firm’s PureProC, a film formulation that protects, stabilizes and delivers the use of vitamin C for duration with anti-aging and skin health benefits. The company was founded Gregory H. Altman and Rebecca Horan in June 2013 and is headquartered in Medford, MA. | - |
| Jeffrey Vinik | M | 65 |
Silk Therapeutics, Inc.
Silk Therapeutics, Inc. Specialty StoresRetail Trade Silk Therapeutics, Inc. provides silk protein solutions for human health. It sells its products through its online store. The firm’s PureProC, a film formulation that protects, stabilizes and delivers the use of vitamin C for duration with anti-aging and skin health benefits. The company was founded Gregory H. Altman and Rebecca Horan in June 2013 and is headquartered in Medford, MA.
Evolved by Nature, Inc.
Evolved by Nature, Inc. TextilesProcess Industries Evolved by Nature, Inc. manufactures activated silk. The firm’s product is pure silk in liquid form, a regenerative technology made from discarded silkworm cocoons. The company was founded by Gregory Altman and Rebecca Lacouture in 2013 and is headquartered in Medford, MA. | - |
| Joseph F. Coughlin | M | 60 |
Massachusetts Institute of Technology
| 25 years |
| Leo Rafael Reif | M | 73 |
Massachusetts Institute of Technology
| 25 years |
| Eva Genel | F | - |
Silk Therapeutics, Inc.
Silk Therapeutics, Inc. Specialty StoresRetail Trade Silk Therapeutics, Inc. provides silk protein solutions for human health. It sells its products through its online store. The firm’s PureProC, a film formulation that protects, stabilizes and delivers the use of vitamin C for duration with anti-aging and skin health benefits. The company was founded Gregory H. Altman and Rebecca Horan in June 2013 and is headquartered in Medford, MA. | - |
| Christine Ortiz | M | 53 |
Massachusetts Institute of Technology
| 25 years |
| Sheri Disney | F | - |
Silk Therapeutics, Inc.
Silk Therapeutics, Inc. Specialty StoresRetail Trade Silk Therapeutics, Inc. provides silk protein solutions for human health. It sells its products through its online store. The firm’s PureProC, a film formulation that protects, stabilizes and delivers the use of vitamin C for duration with anti-aging and skin health benefits. The company was founded Gregory H. Altman and Rebecca Horan in June 2013 and is headquartered in Medford, MA. | - |
| Paul Thompson | M | - |
UMass Chan Medical School
| - |
| Erik Sontheimer | M | - |
UMass Chan Medical School
| - |
| Phillip Zamore | M | - |
UMass Chan Medical School
| - |
| Guang Ping Gao | M | - |
UMass Chan Medical School
| 16 years |
| Maria Zuber | M | 66 |
Massachusetts Institute of Technology
| 29 years |
| Richard V. Aghababian | M | - |
UMass Chan Medical School
| - |
| Nancy L. Rose | M | 64 |
Massachusetts Institute of Technology
| 29 years |
| Dmitry Samarsky | M | 57 |
UMass Chan Medical School
| - |
| Allan Jacobson | M | 78 |
UMass Chan Medical School
| 30 years |
| Nitin Patel | M | - |
Massachusetts Institute of Technology
| 29 years |
| Bruce Auerbach | M | - |
UMass Chan Medical School
| - |
| David G. Lowe | M | 67 |
AllosteRx Capital Management (Canada), Inc.
| - |
| Richard Schmalensee | M | 80 |
Massachusetts Institute of Technology
| 26 years |
| Woody Benson | M | 65 |
Prism Venture Management LLC
 Prism Venture Management LLC Investment ManagersFinance Prism Venture Management LLC (Prism Venture Management) is a venture capital firm founded in 1996 by Bob C. Fleming and John L. Brooks. The firm is headquartered in Needham, Massachusetts. | 20 years |
| Ram Sasisekharan | M | 58 |
Massachusetts Institute of Technology
| 28 years |
| Roy P Disney | M | - |
Evolved by Nature, Inc.
Evolved by Nature, Inc. TextilesProcess Industries Evolved by Nature, Inc. manufactures activated silk. The firm’s product is pure silk in liquid form, a regenerative technology made from discarded silkworm cocoons. The company was founded by Gregory Altman and Rebecca Lacouture in 2013 and is headquartered in Medford, MA. | - |
| Sheila E. Widnall | M | 85 |
Massachusetts Institute of Technology
| 26 years |
| Robert W. Pangia | M | 72 |
Evolved by Nature, Inc.
Evolved by Nature, Inc. TextilesProcess Industries Evolved by Nature, Inc. manufactures activated silk. The firm’s product is pure silk in liquid form, a regenerative technology made from discarded silkworm cocoons. The company was founded by Gregory Altman and Rebecca Lacouture in 2013 and is headquartered in Medford, MA. | - |
| stephen lyle | M | - |
UMass Chan Medical School
| - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jeffrey Stein | M | 69 |
Trius Therapeutics, Inc.
 Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 6 years |
| Ioannis Kymissis | M | - |
Massachusetts Institute of Technology
| 9 years |
| Michael Zhang | M | - |
Massachusetts Institute of Technology
| 11 years |
| Matt Engel | M | - |
Prism Venture Management LLC
Prism Venture Management LLC Investment ManagersFinance Prism Venture Management LLC (Prism Venture Management) is a venture capital firm founded in 1996 by Bob C. Fleming and John L. Brooks. The firm is headquartered in Needham, Massachusetts. | 14 years |
| John Schmid | M | 61 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 9 years |
| Matthew Onaitis | M | 53 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | - |
| Morten Aleksandr Engel | M | - |
Massachusetts Institute of Technology
| 5 years |
| Russ Spieler | M | - |
Massachusetts Institute of Technology
| 5 years |
| Hatice Hale Özsoy Biyikli | F | 47 |
Massachusetts Institute of Technology
| 4 years |
| Rahul Agrawal | M | 44 |
Massachusetts Institute of Technology
| 5 years |
| Richard J. Nelson | M | - |
Massachusetts Institute of Technology
| 5 years |
| Tom Rikert | M | - |
Massachusetts Institute of Technology
| 5 years |
| Patrick Michael McCaney | M | 43 |
Massachusetts Institute of Technology
| 5 years |
| Jonathan Paul Loflin | M | - |
Massachusetts Institute of Technology
| 5 years |
| Hongming Chen | M | 53 |
Massachusetts Institute of Technology
| 3 years |
| Dustin Byrne | M | - |
Massachusetts Institute of Technology
| 5 years |
| Celine Fung | F | - |
Massachusetts Institute of Technology
| 2 years |
| Muhammad Mohsin Al-Saggaf | M | 56 |
Massachusetts Institute of Technology
| 5 years |
| Rob Burn | M | - |
Massachusetts Institute of Technology
| 5 years |
| Eric R. Cosman | M | - |
Massachusetts Institute of Technology
| 5 years |
| Nina Kjellson | F | 49 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 6 years |
| Jinane Abounadi | F | - |
Massachusetts Institute of Technology
| 9 years |
| Tian Hang Hu | M | 46 |
Massachusetts Institute of Technology
| 5 years |
| Ming-Hokng Maa | M | 48 |
Massachusetts Institute of Technology
| 5 years |
| Sami Shalabi | M | - |
Massachusetts Institute of Technology
| 5 years |
| Libby Wayman | F | - |
Massachusetts Institute of Technology
| 7 years |
| David Quiram | M | 49 |
Massachusetts Institute of Technology
| 5 years |
| Michael Minnich | M | 52 |
Massachusetts Institute of Technology
| 4 years |
| Dong-Sik Kim | M | 54 |
Massachusetts Institute of Technology
| 2 years |
| Alexandre Santos | M | - |
Massachusetts Institute of Technology
| 4 years |
| Feng Li | M | 56 |
Massachusetts Institute of Technology
| 4 years |
| Ilya Lisansky | M | - |
Massachusetts Institute of Technology
| 4 years |
| Kathy Chiu | F | - |
Massachusetts Institute of Technology
| 5 years |
| Errol Arkilic | M | - |
Massachusetts Institute of Technology
| 6 years |
| Alan Chhabra | M | - |
Massachusetts Institute of Technology
| 5 years |
| Vishal Kapur | M | - |
Massachusetts Institute of Technology
| 5 years |
| Paul Carey Konigsberg | M | - |
Massachusetts Institute of Technology
| 4 years |
| Young Kim | M | - |
Massachusetts Institute of Technology
| 5 years |
| Wesley Chan | M | - |
Massachusetts Institute of Technology
| 5 years |
| Richard D. Borovoy | M | - |
Massachusetts Institute of Technology
| 5 years |
| Karin Eastham | F | 74 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 6 years |
| Brian Atwood | M | 71 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 6 years |
| Michael Powell | M | 69 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 5 years |
| John Brooks | M | 73 |
Prism Venture Management LLC
Prism Venture Management LLC Investment ManagersFinance Prism Venture Management LLC (Prism Venture Management) is a venture capital firm founded in 1996 by Bob C. Fleming and John L. Brooks. The firm is headquartered in Needham, Massachusetts. | 11 years |
| Paritosh Somani | M | - |
Massachusetts Institute of Technology
| 4 years |
| Jake Seid | M | - |
Massachusetts Institute of Technology
| 2 years |
| Ben Shih | M | - |
Massachusetts Institute of Technology
| 4 years |
| Matthias B. Jaffé | M | 50 |
Massachusetts Institute of Technology
| 3 years |
| Robert Poor | M | - |
Massachusetts Institute of Technology
| 6 years |
| Adnan Lawai | M | - |
Massachusetts Institute of Technology
| 7 years |
| Joseph A. Pignato | M | - |
Prism Venture Management LLC
Prism Venture Management LLC Investment ManagersFinance Prism Venture Management LLC (Prism Venture Management) is a venture capital firm founded in 1996 by Bob C. Fleming and John L. Brooks. The firm is headquartered in Needham, Massachusetts. | - |
| Evren Ünver | M | - |
Massachusetts Institute of Technology
| 5 years |
| Adrianna Ma | F | 50 |
Massachusetts Institute of Technology
| 5 years |
| Peter Rice | M | - |
Massachusetts Institute of Technology
| 6 years |
| Jonathan Sheena | M | 51 |
Massachusetts Institute of Technology
| 6 years |
| Neena Kadaba | M | - |
Massachusetts Institute of Technology
| 5 years |
| Eve Phillips | F | - |
Massachusetts Institute of Technology
| 5 years |
| Mike Capelle | M | - |
Massachusetts Institute of Technology
| 2 years |
| Henry Chung | M | - |
Massachusetts Institute of Technology
| 5 years |
| Kevin Wang | M | - |
Massachusetts Institute of Technology
| 5 years |
| Brian Chen | M | - |
Massachusetts Institute of Technology
| 5 years |
| Shane M. Farritor | M | - |
Massachusetts Institute of Technology
| 5 years |
| Neil Renninger | M | 49 |
Massachusetts Institute of Technology
| 5 years |
| Maria Staton | F | 54 |
Massachusetts Institute of Technology
| 2 years |
| James L. McGrath | M | - |
Massachusetts Institute of Technology
| 5 years |
| Kareem Akhtar | M | - |
Massachusetts Institute of Technology
| 5 years |
| Chris Turner | M | - |
Massachusetts Institute of Technology
| 6 years |
| Kenneth Lau | M | 46 |
Massachusetts Institute of Technology
| 4 years |
| Timothy Lu | M | 43 |
Massachusetts Institute of Technology
| 8 years |
| William Feehery | M | 54 |
Massachusetts Institute of Technology
| 5 years |
| Shalini Agarwal | F | - |
Massachusetts Institute of Technology
| 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 98 | 98.00% |
| Canada | 2 | 2.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Brendan M. O'Leary
- Personal Network
